CD274 and cancer: Combined with anti-PD-L1 and CTLA-4 agents, guadecitabine reduced the growth and metastases in the B16F10 murine melanoma model, which occurred via enhancing effector memory CD8+ T cells and spleen NK cells while also decreasing the activity of cancer-associated lymphocytes in the tumor microenvironment (81).